The researchers developed a novel therapy for cancer patients that harnesses the patient’s own immune system to fight cancer in a natural way.
Company developing immunotherapy treatments for cancer up 139 percent this year.
TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments.
TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
TapImmune would consider a partnership deal with a major pharmaceutical firm overseas.
Markers’ platform has shown promise in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.
TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune has entered in a definitive agreement to acquire Marker Therapeutics.
Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response.